according to the 2021 annual report released on March 18, Huapont Life Sciences Co.Ltd(002004) 3, the company achieved a total operating revenue of 12.359 billion yuan last year, a year-on-year increase of 13.63%; The net profit attributable to the parent company was 670 million yuan, a year-on-year increase of 2.81%; The net profit after deducting non profit was 610 million yuan, an increase of 7.23%, and the earnings per share was 0.34 yuan. The company’s profit distribution plan for the 21st year is 2.20 yuan (including tax) for 10 dividends.
It is understood that in 2021, the company firmly implemented the “great health” development strategy of medicine and medical treatment, and continued to improve the whole industry chain development model integrating API, preparation, functional skin care products, pan skin health management and medical services. In terms of medicine, strengthen new product research and development and product layout, consolidate the leading position in the prescription market, and actively explore the retail market outside the hospital; Launch a variety of functional skin care products and skin medical devices to further extend the pan skin health industry chain; Make use of the surplus production capacity to actively develop cdmo business of APIs and preparations.
In terms of medical treatment, Kuanren hospital in northern Chongqing continued to maintain rapid development, with an annual revenue of 295 million yuan, a year-on-year increase of 2.8 times. The discipline structure was further improved, the number of visits increased steadily and the medical level was continuously improved; Beijing Huasheng rehabilitation hospital has been successfully opened. At present, it has been included in the designated medical institutions of Beijing medical insurance. In the follow-up, it will further improve the discipline construction and cultivate the talent echelon to achieve better development.
The agrochemical and new materials sectors were separated and listed respectively. Yingtai biology was transferred from the selected layer to the Beijing stock exchange, and Shandong Kaisheng New Materials Co.Ltd(301069) was issued and listed on the gem of Shenzhen Stock Exchange. From the perspective of business structure, the company further clarified its business layout and realized light loading. In terms of tourism, the impact of the epidemic is relatively serious. Yunnan Province has suspended inter provincial tourism activities three times. At present, the company is actively and orderly resuming tourist reception according to the requirements of the government.
Looking forward to 2022, Huapont Life Sciences Co.Ltd(002004) said that it would continue to focus on the main business of “great health” of medicine and medical treatment, and continue to improve the whole industry chain development model integrating API, preparation, functional skin products, pan skin health management and medical services. Among them, in medicine, strengthen the leading position in the prescription market, actively expand the retail market outside the hospital, actively develop cosmetics and machinery products, build the first brand of “big skin” in China, and use the new production capacity to develop the cdmo business of APIs and preparations. In terms of medical treatment, we should give full play to the synergy of 100 million yuan both at home and abroad, improve discipline construction, cultivate talent echelons, maintain the continuous growth of the number of patients, steadily improve the medical level, continue to promote Innovation Medical Management Co.Ltd(002173) business, and actively explore the combination of health and tourism projects in combination with its rich tourism resources.
In addition, the company will continue to maintain the independent and steady operation of its three listed companies, Yingtai biology, Shandong Kaisheng New Materials Co.Ltd(301069) , Lijiang Yulong Tourism Co.Ltd(002033) and give full play to the key role of controlling shareholders in the governance of its three sessions and continuously enhance its profitability.
